**GRAIL, Inc. Reports Fiscal Year 2025 Results, Highlights Progress in Early Cancer Detection**
GRAIL, Inc., a commercial-stage healthcare company focused on multi-cancer early detection (MCED), released its financial results for the fiscal year 2025, reporting total revenue of $147.2 million, a 17% increase compared to $125.6 million in 2024. Screening revenue, primarily from sales of its Galleri test, reached $138.6 million, up 28% from $108.6 million in the previous year, driven by a 36% increase in test volume, partially offset by a 6% decrease in average selling price (ASP). Development services revenue, however, declined by 49% to $8.6 million from $17.0 million in 2024, due to decreased revenue from pilots with biopharmaceutical partners and research services. The company's net loss for the year was $408.4 million, a significant improvement from the $2.0 billion loss in 2024, primarily due to a decrease in goodwill and intangible asset impairment charges.
The company's cost of screening revenue (exclusive of amortization of intangible assets) was $73.3 million, representing 53% of screening revenue, compared to 58% in the prior year. Research and development expenses decreased by 39% to $195.8 million, reflecting the completion of key clinical trials and a strategic focus on the core MCED business. Sales and marketing expenses also decreased by 24% to $116.7 million, while general and administrative expenses fell by 26% to $159.1 million, both attributed to cost optimization efforts and workforce reductions. The company's cash and cash equivalents totaled $249.7 million, with short-term marketable securities at $654.7 million as of December 31, 2025.
Operationally, GRAIL highlighted the submission of its pre-market approval (PMA) application to the FDA for the Galleri test in January 2026. The submission included data from the NHS-Galleri Trial and the PATHFINDER 2 study. The company also emphasized its ongoing collaboration with Samsung for commercialization in South Korea and other Asian markets, pending regulatory approvals. GRAIL has sold more than 475,000 commercial tests, including more than 185,000 tests in 2025. The company is also enrolling up to 50,000 Medicare beneficiaries in its REACH/Galleri-Medicare study designed to evaluate the clinical impact of the Galleri MCED test among Medicare beneficiaries, including racial and ethnic minorities, and seniors from historically underserved communities.
Looking ahead, GRAIL anticipates continued investment in clinical evidence generation and regulatory efforts to support broad adoption of Galleri. The company expects research and development expenses to decrease over the next three years as key clinical trials progress into the data follow-up phase. GRAIL also plans to leverage its existing infrastructure to scale operations and improve margins. However, the company acknowledges the need for additional financing to support its commercialization efforts and product development pipeline. The company is also subject to a number of risks and uncertainties, including the potential for product liability claims, reliance on sole suppliers, and the evolving regulatory landscape for laboratory-developed tests.
About GRAIL, Inc.
GRAIL, Inc. develops multi-cancer early detection (MCED) blood tests, primarily through its Galleri platform, to identify over 50 cancer types at early stages. Its products aim to complement existing screening guidelines, improve early diagnosis, and reduce cancer mortality. The company leverages proprietary methylation technology, extensive clinical data, and strategic partnerships to expand access, gain regulatory approval, and establish a new standard in population-wide cancer screening.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.